Shares of Caladrius Biosciences (CLBS) are surging after H.C. Wainwright initiated a buy rating with a price target of $14. Caladrius Biosciences is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly of cardiovascular disease.
The company was founded in 1980 and was formerly known as Corniche Group Inc, Phase III Medical Inc, and NeoStem, Inc. The company stock currently has a market cap $83 million and an average trading of volume of about 400,000.
